ConductScience.org, home

Paper55716

Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis.

Cochrane AM and 4 others. Lancet, 1976. Cited by 230 papers, by iCite.

Cite this record

ConductScience Library. Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Papers, record 55716. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/55716

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis.
PubMed
Journal
Lancet
PubMed
Year
1976
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
230
iCite
Relative citation ratio, by iCite
6.79
iCite
Revised in PubMed
2019-06-10
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cochrane AMA M
2Moussouros AA
3Thomsom ADA D
4Eddleston ALA L
5Wiiliams RR

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Autoimmune DiseasesMajor topic
Cytotoxicity Tests, ImmunologicMajor topic
HepatitisMajor topic
LiverMajor topic
Adult
Aged
Autoantibodies
B-Lymphocytes
Chronic Disease
Culture Techniques
Female
Humans
Lipoproteins
Liver Function Tests
Male
Middle Aged
T-Lymphocytes

Source PubMed

Download CSV of topics

Cited by89

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 230 citations.

PMIDTitleJournalYearIn PapersSource
41014384Piceatannol improves autoimmune hepatitis by inhibiting the immune activities of T cells and macrophages through binding with c-Jun.Immunol Res2025https://conductscience.org/library/papers/41014384PubMed
39117005B and T cells: (Still) the dominant orchestrators in autoimmune hepatitis.Autoimmun Rev2024https://conductscience.org/library/papers/39117005PubMed
38404291The significance of gut microbiota in the etiology of autoimmune hepatitis: a narrative review.Front Cell Infect Microbiol2024https://conductscience.org/library/papers/38404291PubMed
35100095Pathogenicity and virulence of Hepatitis B virus.Virulence2022https://conductscience.org/library/papers/35100095PubMed
34650567Dysfunctional Immune Regulation in Autoimmune Hepatitis: From Pathogenesis to Novel Therapies.Front Immunol2021https://conductscience.org/library/papers/34650567PubMed
33652348Regulatory T cells in autoimmune hepatitis: an updated overview.J Autoimmun2021https://conductscience.org/library/papers/33652348PubMed
30599169Immunogenicity of Protein Pharmaceuticals.J Pharm Sci2019https://conductscience.org/library/papers/30599169PubMed
28512353Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG.Sci Rep2017https://conductscience.org/library/papers/28512353PubMed
26000135Asialoglycoprotein receptor (ASGPR): a peculiar target of liver-specific autoimmunity.Auto Immun Highlights2012https://conductscience.org/library/papers/26000135PubMed
19452572Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.World J Gastroenterol2009https://conductscience.org/library/papers/19452572PubMed
9951951Drug therapy in the management of type 1 autoimmune hepatitis.Drugs1999https://conductscience.org/library/papers/9951951PubMed
7851212Autoimmune hepatitis. Evolving concepts and treatment strategies.Dig Dis Sci1995https://conductscience.org/library/papers/7851212PubMed
7450561Autoantibodies against liver-specific membrane lipoprotein in acute and chronic liver diseases: studies on organ-, species-, and disease-specificity.Gut1980https://conductscience.org/library/papers/7450561PubMed
7436533Immune responses to liver membrane antigens in patients with cystic fibrosis and liver disease.Arch Dis Child1980https://conductscience.org/library/papers/7436533PubMed
7379331Cell-mediated immunity to liver antigen in toxic liver injury. I. Occurrence and specificity.Clin Exp Immunol1980https://conductscience.org/library/papers/7379331PubMed
7318258Natural killer activity in patients with biopsy-proven liver disease.Clin Exp Immunol1981https://conductscience.org/library/papers/7318258PubMed
7307345Histological and immunological investigation of liver-specific protein (LSP) immunized rabbits compared with patients with liver disease.Clin Exp Immunol1981https://conductscience.org/library/papers/7307345PubMed
7286562Antibody dependent cellular cytotoxicity in chronic active liver diseases.Gastroenterol Jpn1981https://conductscience.org/library/papers/7286562PubMed
7251131Influence of (+)-cyanidanol-3 on the leukocyte migration inhibition test carried out in the presence of purified protein derivative and hepatitis B surface antigen.Infect Immun1981https://conductscience.org/library/papers/7251131PubMed
7227762Pathological study of chronic D-galactosamine induced hepatitis in mice by administration of adjuvants - an animal model of the chronic active hepatitis.Gastroenterol Jpn1981https://conductscience.org/library/papers/7227762PubMed

See all 89 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/55716

GET https://conductscience.org/api/papers/v1/55716/cited_by?page=2